Eh.

Broadly neutralizing antibodies has continued to be an oversold premise in regards to making vaccines that are "universal."

There was a guy at Mount Sinai who pushed universal influenza vaccines for decades with cross reactive antibodies being a major pillar of the approach.

Well, as it turns out, improved methodologies to measure and characterize B cell responses have shown that we make cross reactive antibodies during natural infection, often to targets that were thought holy grails of a "universal" response (ie the stalk region of influenza HA protein).

But we clearly don't develop "universal" responses that negate the need for seasonal influenza vaccines.

I suspect this vaccine will end up the same way.